/images/ppid_59c68470-image-178196502282037510.webp)
/images/ppid_59c68470-image-178171252832443983.webp)
/images/ppid_59c68470-image-178177755888282687.webp)
What is the story about?
Sun Pharmaceutical Industries Ltd said on Saturday, June 20, that it has entered into an agreement to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Ltd for a cash consideration of approximately ₹271.2 crore.
Mumbai-based Innovcare Lifesciences is engaged in the marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products.
Sun Pharma said the acquisition is a strategic investment aimed at strengthening its product portfolio.
The company added that the transaction is not a related-party deal and that neither the promoter nor the promoter group has any interest in the target entity.
As per the exchange fillings, the acquisition is expected to be completed on or before July 31, 2026.
Q4FY26 Results
For the quarter ended March, Sun Pharma's profitability grew by 26% from last year to ₹2,714 crore, which is in-line with the CNBC-TV18 poll of ₹2,742 crore.
Company's revenue for the quarter stood at ₹14,612 crore, a growth of 12.8% compared to the previous year's figure of ₹12,959 crore. The figure is also marginally higher than the CNBC-TV18 poll of ₹14,528.1 crore.
EBITDA margin for the period narrowed by 160 basis points from last year to 27.1% from 28.7% last year and the number was also lower than the CNBC-TV18 poll figure of 27.8%.
Shares of Sun Pharmaceutical Industries Ltd ended 0.85% higher at ₹1,840.40 on June 19 at NSE.
Also Read: Low-cost imports and high input costs to weigh on paper industry margins: CareEdge Ratings
Mumbai-based Innovcare Lifesciences is engaged in the marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products.
Sun Pharma said the acquisition is a strategic investment aimed at strengthening its product portfolio.
The company added that the transaction is not a related-party deal and that neither the promoter nor the promoter group has any interest in the target entity.
As per the exchange fillings, the acquisition is expected to be completed on or before July 31, 2026.
Q4FY26 Results
For the quarter ended March, Sun Pharma's profitability grew by 26% from last year to ₹2,714 crore, which is in-line with the CNBC-TV18 poll of ₹2,742 crore.
Company's revenue for the quarter stood at ₹14,612 crore, a growth of 12.8% compared to the previous year's figure of ₹12,959 crore. The figure is also marginally higher than the CNBC-TV18 poll of ₹14,528.1 crore.
EBITDA margin for the period narrowed by 160 basis points from last year to 27.1% from 28.7% last year and the number was also lower than the CNBC-TV18 poll figure of 27.8%.
Shares of Sun Pharmaceutical Industries Ltd ended 0.85% higher at ₹1,840.40 on June 19 at NSE.
Also Read: Low-cost imports and high input costs to weigh on paper industry margins: CareEdge Ratings
/images/ppid_59c68470-image-178187502873335617.webp)
/images/ppid_59c68470-image-178196252537553000.webp)
/images/ppid_59c68470-image-178189254107434813.webp)
/images/ppid_59c68470-image-178170255358914507.webp)
/images/ppid_59c68470-image-178168758695296595.webp)